Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox

TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models

Read more at globenewswire.com